Adage Capital Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Adage Capital Partners’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.6M	Sell	375,000 -92,468	-20%	-$8.7M	0.05%	332
2025 Q4	$36.9M	Sell	467,468 -30,000	-6%	-$2.15M	0.06%	321
2025 Q3	$36.5M	Buy	497,468 +254,468	+105%	+$16.2M	0.06%	308
2025 Q2	$12.4M	Sell	243,000 -102,000	-30%	-$4.54M	0.02%	568
2025 Q1	$15.5M	Buy	345,000 +195,000	+130%	+$9.19M	0.03%	476
2024 Q4	$6.2M	Buy	150,000 +70,000	+88%	+$2.92M	0.01%	692
2024 Q3	$3.12M	Sell	80,000 -80,000	-50%	-$3.19M	0.01%	752
2024 Q2	$5.47M	Hold	160,000	–	–	0.01%	703
2024 Q1	$4.02M	Sell	160,000 -415,000	-72%	-$11.4M	0.01%	720
2023 Q4	$17M	Sell	575,000 -90,000	-14%	-$2.72M	0.04%	468
2023 Q3	$21M	Buy	+665,000	New	+$18.2M	0.05%	381

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners's MIRM Position: Q1 2026 in Review

Adage Capital Partners reduced its Mirum Pharmaceuticals (MIRM) stake by 20% in Q1 2026, selling an estimated $8.7M and leaving 375,000 shares worth $34.6M. The position accounts for 0.05% of the portfolio, ranked #332.

Adage Capital Partners first reported a position in MIRM in Q3 2023 and has held it in 11 quarters since. The position peaked at $36.9M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Adage Capital Partners held 375,000 shares of Mirum Pharmaceuticals worth $34.6M as of Q1 2026.
Adage Capital Partners sold 92,468 Mirum Pharmaceuticals shares in Q1 2026, an estimated $8.7M.
Mirum Pharmaceuticals made up 0.05% of Adage Capital Partners's portfolio in Q1 2026, its #332 holding.
Adage Capital Partners first reported a position in Mirum Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Adage Capital Partners's Mirum Pharmaceuticals position peaked at $36.9M in Q4 2025.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.